ABN Amro Investment Solutions Sells 5,599 Shares of Gilead Sciences, Inc. $GILD

ABN Amro Investment Solutions lowered its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 3.2% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 172,050 shares of the biopharmaceutical company’s stock after selling 5,599 shares during the quarter. ABN Amro Investment Solutions’ holdings in Gilead Sciences were worth $23,979,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors also recently bought and sold shares of GILD. PNC Financial Services Group Inc. lifted its holdings in Gilead Sciences by 2.6% in the first quarter. PNC Financial Services Group Inc. now owns 486,271 shares of the biopharmaceutical company’s stock worth $67,772,000 after buying an additional 12,166 shares during the period. Oslo Pensjonsforsikring AS purchased a new stake in Gilead Sciences in the first quarter worth $648,000. Baader Bank Aktiengesellschaft raised its holdings in Gilead Sciences by 19.0% in the first quarter. Baader Bank Aktiengesellschaft now owns 8,320 shares of the biopharmaceutical company’s stock worth $1,088,000 after purchasing an additional 1,327 shares in the last quarter. Wilkerson Advisory Group LLC raised its holdings in Gilead Sciences by 54.2% in the first quarter. Wilkerson Advisory Group LLC now owns 222 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 78 shares in the last quarter. Finally, Glenview Trust Co lifted its position in Gilead Sciences by 1.4% during the first quarter. Glenview Trust Co now owns 192,157 shares of the biopharmaceutical company’s stock valued at $26,781,000 after buying an additional 2,683 shares during the period. 83.67% of the stock is owned by institutional investors.

Gilead Sciences Price Performance

GILD opened at $130.28 on Wednesday. The company’s 50-day simple moving average is $129.63 and its two-hundred day simple moving average is $135.42. Gilead Sciences, Inc. has a 52-week low of $108.06 and a 52-week high of $157.29. The stock has a market capitalization of $161.75 billion, a P/E ratio of 17.75 and a beta of 0.32. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.77 and a current ratio of 1.97.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share for the quarter, beating analysts’ consensus estimates of $1.91 by $0.12. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. The company had revenue of $6.96 billion for the quarter, compared to the consensus estimate of $6.91 billion. During the same quarter in the prior year, the firm earned $1.81 earnings per share. The firm’s revenue for the quarter was up 4.4% compared to the same quarter last year. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. As a group, analysts predict that Gilead Sciences, Inc. will post -0.77 EPS for the current year.

Gilead Sciences Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, June 29th. Stockholders of record on Monday, June 15th were paid a $0.82 dividend. This represents a $3.28 annualized dividend and a dividend yield of 2.5%. The ex-dividend date was Monday, June 15th. Gilead Sciences’s dividend payout ratio is 44.69%.

Wall Street Analyst Weigh In

A number of analysts have recently commented on GILD shares. Daiwa Securities Group dropped their target price on shares of Gilead Sciences from $161.00 to $150.00 and set an “outperform” rating on the stock in a report on Tuesday, May 19th. Wall Street Zen upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating in a research note on Sunday, July 12th. Morgan Stanley lowered their target price on shares of Gilead Sciences from $168.00 to $166.00 and set an “overweight” rating for the company in a report on Wednesday, July 8th. Weiss Ratings cut Gilead Sciences from a “buy (b)” rating to a “buy (b-)” rating in a research report on Thursday, May 28th. Finally, The Goldman Sachs Group lifted their price objective on Gilead Sciences from $125.00 to $130.00 and gave the company a “neutral” rating in a research note on Friday, April 17th. Twenty-five analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $158.33.

Insider Buying and Selling

In related news, CEO Daniel Patrick O’day sold 15,000 shares of the business’s stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $126.29, for a total transaction of $1,894,350.00. Following the completion of the sale, the chief executive officer directly owned 607,133 shares in the company, valued at approximately $76,674,826.57. The trade was a 2.41% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of the company’s stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $125.40, for a total transaction of $376,200.00. Following the sale, the chief financial officer directly owned 171,646 shares of the company’s stock, valued at approximately $21,524,408.40. This represents a 1.72% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 77,000 shares of company stock valued at $9,978,740. 0.30% of the stock is owned by insiders.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.